Does Elan's narrower loss mean its troubles are over?

Is this a new dawn for Elan? Has the Irish pharmaceutical company finally turned that corner? It has claimed to have done so several times in the past and then--bam!--another unforeseen event came out of nowhere. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.